Credit Card-Sized Device Offers 12-Lead ECG Readout for Remote Heart Attack Detection - Daily clinical news - mobile.Hospimedica.com

By HospiMedica International unit writers
Posted connected 09 Dec 2022

In the US, astir 18 cardinal individuals person coronary artery illness putting them astatine an accrued hazard for a bosom onslaught and making them perfect candidates for distant diligent bosom onslaught detection. In contrast, the marketplace for atrial fibrillation, the astir targeted information for detection by single-lead ECG technologies, is respective times smaller. A 12-lead ECG is the modular of attraction for detecting immoderate cardiac information and is considered 1 of the indispensable tools for bosom onslaught detection. No azygous pb ECG merchandise presently successful the marketplace is capable to assistance diagnose a bosom attack. Now, a patented exertion allows a recognition card-sized instrumentality to alteration a 12-lead ECG anytime, anywhere.

HeartBeam, Inc. (Santa Clara, CA, USA), a cardiac exertion institution that has developed the archetypal and lone 3D-vector ECG level for bosom onslaught detection anytime, anywhere, was precocious issued a patent by the United States Patent and Trademark Office that enables procreation of a synthesized 12-lead ECG by the HeartBeam AIMIGo recognition card-sized device. The innovation opens the pathway for a diligent to grounds a acceptable of signals utilizing HeartBeam AIMIGo extracurricular of a aesculapian mounting with a diagnostic synthesized 12-lead ECG instantly transmitted to a doc for reappraisal and diagnosis. Unlike single-lead ECG products presently successful the marketplace, specified arsenic different recognition paper sized devices oregon smartwatches, the HeartBeam exertion is intended to rapidly and accurately assistance a doc place a bosom onslaught (myocardial infarction).

The recently issued patent expands connected HeartBeam’s granted and pending halfway patents for distant bosom onslaught detection. The worth of the precocious granted 12-lead ECG spot patent is successful addressing the marketplace request for multi-week, continuous monitoring portion the AIMIGo solution is ever with the patient, providing a means for timely bosom onslaught intervention. This whitethorn summation prime of beingness for cardiac patients by reducing the fearfulness of thorax symptom and supply added bid of mind. At the halfway of some products is HeartBeam’s breakthrough quality to supply a patient-friendly means of obtaining a 12-lead ECG anytime, anywhere.

“This patent provides further intelligence spot extortion for our breakthrough AIMIGo exertion offering 12-lead ECG capableness successful the signifier of a recognition card-sized instrumentality with the aforesaid footprint arsenic the single-lead products presently successful the marketplace today,” said HeartBeam CEO and Founder Branislav Vajdic, PhD. “Our 12-lead AIMIGo technology, which is portion of our granted patent, offers the imaginable to bring a level of diagnostic accuracy accordant with the existent 12-lead ECG modular of care. This could trim the captious clip to involution for bosom onslaught patients, redeeming lives and reducing healthcare costs by ruling retired a bosom onslaught and reducing the fig of exigency country visits.”

Related Links:
HeartBeam, Inc.